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HIV-1 exploits the cellular machinery for replication and therefore several interactions with cellular
factors take place, some of which are yet unknown. We identiﬁed GTPase-activating protein-(SH3
domain)-binding protein 1 (G3BP1) as a cellular factor that restricts HIV-1, by analyzing transcriptome
proﬁles of in vitro-cytokine-activated macrophages that are non-permissive to HIV-1 replication. Silen-
cing of G3BP1 by RNA interference resulted in increased HIV-1 replication in primary T-cells and mac-
rophages, but did not affect replication of other retroviruses. G3BP1 speciﬁcally interacted with HIV-1
RNA in the cytoplasm, suggesting that it sequesters viral transcripts, thus preventing translation or
packaging. G3BP1 was highly expressed in resting naïve or memory T-cells from healthy donors and HIV-
1 infected patients, but signiﬁcantly lower in IL-2-activated T-cells. These results strongly suggest that
G3BP1 captures HIV-1 RNA transcripts and thereby restricts mRNA translation, viral protein production
and virus particle formation.
& 2015 Elsevier Inc. All rights reserved.Introduction
Antiretroviral therapy has dramatically improved the clinical
outcome of HIV-1 infection. However, total eradication of HIV-1
cannot be entirely achieved, due to the persistence of viral reservoirs
that allows for continuous residual viral replication and dissemina-
tion of the infection, while avoiding triggering of immune responses.
Indeed, plasma viral load in HIV-1 infected patients can very rapidly
rebound after stopping therapy (Chun et al., 1999; Harrigan et al.,
1999; Palmer et al., 2008). Macrophages become highly susceptible
to HIV-1 infection after they differentiate from monocytic precursors
(Rich et al., 1992; Schuitemaker et al., 1992; Sonza et al., 1996). HIV-1
infected macrophages found in the tissues of HIV-1 infected patients
(Koenig et al., 1986) allow for residual viral replication at sites such as
the gut-associated lymphoid tissue and the brain, even during anti-
retroviral therapy (Chun et al., 2008; Eisele and Siliciano, 2012;
Lambotte et al., 2005). Thus, macrophages play a crucial role in thePathogenesis, Department of
r, Room M01-120, Meiberg-
nds. Tel.: þ31 20 5668298;
otstra).maintenance and dissemination of the infection. Their importance is
further underscored by studies showing that they are highly resistant
to the cytopathic effects of viral replication, and are able to render
resting T-cells permissive for HIV-1 infection (Ancuta et al., 2006;
Swingler et al., 2003). HIV-1 can only replicate in activated pro-
liferating T-cells, where the proviral genome is integrated into the
host genome. In vivo, these cells can go into a resting memory state,
and become latent viral reservoirs (Finzi et al., 1997). These cells
persist during long term therapy and are able to efﬁciently reinitiate
virus production upon stopping therapy (Chun et al., 1997; Finzi
et al., 1997; Wong et al., 1997).
The phenotype and function of macrophages are greatly
determined by their activation by cytokines while differentiating
in the tissues. We and others have previously shown that
cytokine-mediated activation of macrophages results in inhibition
of HIV-1 replication at different stages of the replication cycle: in
IL-4 activated macrophages, HIV-1 is inhibited at the level of
reverse transcription, whereas IFNγþTNFα and IL-10 stimulation
leads to restriction of later stages in the replication cycle (Cassetta
et al., 2013; Cassol et al., 2009; Cobos Jiménez et al., 2012). Several
new cellular factors have been identiﬁed to restrict early steps of
HIV-1 replication upon type 1 interferon stimulation of
V. Cobos Jiménez et al. / Virology 486 (2015) 94–104 95macrophages, such as MX2 (Goujonet al., 2013), IFI16 (Jakobsen et
al., 2013) and SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011;
Lahouassaet al., 2012), or MCPIP1 in activated CD4þ T cells (Liu
et al., 2013). There is however a lack of knowledge regarding cel-
lular factors that affect post-integration steps and thereby allowFig. 1. IFNγþTNFα stimulation of macrophages induces G3BP1 expression. (A) Hier
(Mo) into macrophages (MΦ) for 5 days and stimulation with IFNγþTNFα (50 U/ml a
(B) Genes that were regulated only by stimulation with IFNγþTNFα were selected
(C) Hierarchical clustering of expression of the PMT selected genes in monocytes (Mo), u
ml), IL-4 (50 ng/ml) or IL-10 (50 ng/ml), using median centered values. The location of
keeping gene, in monocytes and macrophages cultured for 1 to 7 days without cytoki
housekeeping gene, in monocytes, and unstimulated macrophages (MΦ) or stimulated
5 days. (F) Expression of G3BP1 relative to a housekeeping gene, in unstimulated macro
(50 U/ml and 12.5 ng/ml). Signiﬁcant differences in the expression levels are indicated b
po0.01**, po0.001***).infected cells that harbor an integrated provirus to persist as viral
reservoirs and remain undetected by the immune system.
Therefore, we aimed to identify cellular factors that could
restrict HIV-1 replication in primary cells. For this purpose, we
compared gene transcriptome proﬁles of permissive macrophages
with those of non-permissive/ IFNγþTNFα activatedarchical clustering of genes signiﬁcantly induced during maturation of monocytes
nd 12.5 ng/ml) for 5 days, using average median-centered values from 2 donors;
by a Pavlidis Template Matching (PMT) analysis, using median-centered values;
nstimulated macrophages (MΦ), or cells stimulated for 5 days with M-CSF (50 ng/
G3BP1 is indicated on the right side; (D) Expression of G3BP1 relative to a house-
ne stimulation, and isolated from 5 donors; (E) Expression of G3BP1 relative to a
with IFNγþTNFα (50 U/ml and 12.5 ng/ml), IL-4 (50 ng/ml) and IL10 (50 nl/ml) for
phages (MΦ) or stimulated with IFNγ (50 U/ml), TNFα (12.5 ng/ml) or IFNγþTNFα
y asterisks (One-way ANOVA and Bonferroni’s Multiple Comparison Test, po0.05*,
V. Cobos Jiménez et al. / Virology 486 (2015) 94–10496macrophages. HIV-1 is restricted after integration in these acti-
vated macrophages (Cobos Jiménez et al., 2012; Cassol et al.,
2009), and therefore with this strategy we could identify novel
restriction factors that act at late stages of the viral cycle. We have
identiﬁed a cellular factor that restricts HIV-1 at post-integration
steps by sequestering viral RNA transcripts, and possibly altering
translation and packaging. Identiﬁcation of cellular factors that
affect post-integration steps contributes to our understanding of
HIV-1 replication and persistence in primary cells, and provides
tools to design novel therapeutic alternatives.Results
G3BP1 is expressed in non-permissive macrophages
To identify novel HIV-1 restriction factors that block replication
after proviral integration, we compared genome-wide transcrip-
tional proﬁles of human macrophages with those of IFNγþTNFα-
stimulated macrophages (Fig. 1A), where HIV-1 infection is
restricted at a post-integration level (Cobos Jiménez et al., 2012).
We identiﬁed 120 genes that were differentially regulated in
IFNγþTNFα stimulated macrophages, but not during differentia-
tion of monocytes into macrophages (Fig. 1B). Expression of most
of the 120 selected genes was exclusively regulated by IFNγþTNFα
stimulation, and changes in expression were neither observed in
IL-4, IL-10 nor M-CSF-stimulated macrophages (Fig. 1C). From the
initial selection, only 4 genes were previously identiﬁed in siRNA/
shRNA genomic screens as host factors required for HIV-1 repli-
cation (Brass et al., 2008; Konig et al., 2008; Yeung et al., 2009;
Zhou et al., 2008). Another 19 genes either possessed antiviral
characteristics or could be involved in viral infections according to
the Ingenuity Knowledge Database (Table 1). One of these genes
was MX1, recently reported to be an IFN-α induced gene, capable
of inhibiting inﬂuenza virus but not HIV-1 replication (Goujon
et al., 2013). These data conﬁrm that our selection strategy isTable 1
Genes with antiviral characteristics, expressed in macrophages stimulated with IFNγ an
TypeSymbol Entrez gene name
Enzyme
G3BP1 GTPase activating protein (SH3 domain) binding protein 1
MX1 Myxovirus (inﬂuenza virus) resistance 1, interferon-inducible protein
NCF1 Neutrophil cytosolic factor 1
RARRES3 Retinoic acid receptor responder (tazarotene induced) 3
RHOC ras homolog family member C
TKT Transketolase
TRIM21 Tripartite motif containing 21
G-protein coupled receptor
AGTRAP Angiotensin II receptor-associated protein
Kinase
IKBKE Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase
MERTK C-mer proto-oncogene tyrosine kinase
Ligand-dependent nuclear receptor
PPARG Peroxisome proliferator-activated receptor gamma
Peptidase
PSMB9 Proteasome (prosome, macropain) subunit, beta type, 9 (large multifu
Transcription regulator
CEBPD CCAAT/enhancer binding protein (C/EBP), delta
STAT1 Signal transducer and activator of transcription 1, 91 kDa
TRIM22 Tripartite motif containing 22
Transmembrane receptor
TLR4 Toll-like receptor 4
Other
IFI35 Interferon-induced protein 35
SDC2 Syndecan 2
TXNIP Thioredoxin interacting proteinsuitable to identify novel antiviral genes. Notably, one of the genes
that was strongly upregulated in IFNγþTNFα-activated macro-
phages was G3BP1, which has been shown to be involved in
infection by viruses such as Hepatitis C Virus, Dengue virus and
members of the Arenavirus genus (Reineke and Lloyd, 2013).
To conﬁrm the results from the transcriptome analyses, we
measured G3BP1 levels in both monocytes and macrophages from
additional donors. During maturation of monocytes into macro-
phages, G3BP1 levels increased on the ﬁrst day of culture, but
decreased progressively until they reach similar levels as those
found in monocytes, after day 5 of differentiation (Fig. 1D). G3BP1
mRNA levels increased strongly upon stimulation of macrophages
with IFNγþTNFα, but not with other cytokines (Fig. 1E), IFNγ
alone or TNFα alone (Fig. 1F).
G3BP1 restricts HIV-1 replication
To investigate the effect of G3BP1 on HIV-1 infection, we
silenced G3BP1 expression in HEK293T cells with shRNA (Fig. 2A)
and measured replication of a VSV-g-pseudotyped HIV-1-lucifer-
ase reporter virus (Fig. 2B). Notably, upon silencing of G3BP1, HIV-
1 replication was signiﬁcantly increased in a dose dependent
manner (Fig. 2B). Additionally, silencing of G3BP1 also led to a
dose dependent increase of luciferase expression from a HIV-1 LTR
reporter construct (Fig. 2C), We have previously shown that in
primary macrophages stimulated with IFNγþTNFα, where G3BP1
is highly expressed, there is no inhibition of viral entry or reverse
transcription (Cobos Jiménez et al., 2012). Here we observed that
silencing of G3BP1 did not affect HIV-1 proviral DNA levels
(Fig. 2D) but did result in increased levels of Pol mRNA copies
(Fig. 2E), higher production of virus particles (Fig. 2F) and viral
protein production (Fig. 2G). Together these results indicate that
G3BP1 regulates HIV-1 replication at a post-transcriptional step.
To explore whether G3BP1 could also affect replication of other
retroviruses, we silenced G3BP1 in 293T cells and inoculated these
cells with VSV-g-pseudotyped SIVmac and MLV-luciferase reporterd TNFα.
Fold change IFNγþTNFα vs Mφ Location
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Fig. 2. G3BP1 restricts HIV-1 replication at a post-integration level. (A) 293T cells were transfected with 50 ng of shRNA-3 targeting G3BP1or shRNA control and sub-
sequently inoculated with single round-luciferase reporter NL4-3 Luciferase virus. 48 h after inoculation, cells were harvested for RNA isolation. G3BP1 mRNA was measured
by qPCR, and levels were normalized to a housekeeping gene. (B) 293T cells transfected with shRNA-3 targeting G3BP1 (50 ng, 25 ng, 12.5 ng and 6.25 ng) or shRNA control
(50 ng), subsequently inoculated with VSV-g/NL4-3Luc and luciferase levels were measured 48 h later. Bars represent the average luciferase activity of triplicate mea-
surements and the error bars represent the standard error of the mean (SEM); (C) 293T cells were transfected with shRNA targeting G3BP1(50 ng, 25 ng, 12.5 ng and 6.25 ng)
or shRNA control (50 ng), together with the HIV-1 LTR Luciferase reporter construct (10 ng); luciferase levels were measured 48 h after transfection. Bars represent the
average luciferase activity of triplicate measurements and the error bars represent the Standard Error of the Mean (SEM). The results from experiments show in A–C are
representative of 3 independent experiments. (D and E) 293T cells were transfected with 50 ng of shRNA targeting G3BP1 or shRNA control and subsequently inoculated with
VSV-g/NL4-3Luc. Proviral DNA (D) and HIV-1 Pol mRNA (E) were measured in DNA and RNA samples isolated 48 and 72 h post-inoculation, and levels were normalized to a
housekeeping gene. The results from experiments show in (D and E) are representative of 2 independent experiments. (F and G) 293T cells were transfected with 100 ng of
pNL4-3BaL and 100 ng of shRNA targeting G3BP1 or shRNA control. (F) Capsid protein p24 was measured in supernatant samples collected every day, by ELISA. Differences
between shRAN-G3BP1 treatment and the control were analyzed by linear regression. (G) Cell lysates were collected and p24 and β-actin protein levels were measured by
Western blot, in triplicate and quantiﬁed. The levels of p24 are relative to β-actin. Signiﬁcant differences are indicated by asterisks (one-way ANOVA test and subsequent
Bonferroni’s multiple comparison test, Students T-test, po0.05*, po0.01**, po0.001***).
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neither affect replication of SIVmac nor MLV (Fig. 3A). Similarly,
G3BP1 down-regulation only affected HIV-1 LTR-driven luciferase
expression (Fig. 3B), whereas SIVmac-LTR and MLV LTR-dependent
luciferase activity was not altered (Fig. 3C-D). G3BP1 down-
regulation enhanced luciferase expression driven by Hepatitis B
Virus S1 promoter, although the difference was not statistically
signiﬁcant; whereas it did neither affect expression driven by the
HBV core promoter, Cytomegalovirus (CMV) promoter nor the
human elongation Factor 1α (eF1α) promoter (Fig. 3E–H). Thesedata strongly indicate that G3BP1 restricts HIV-1 replication at the
level of post-integration, but does not affect replication of other
retroviruses.G3BP1 binds HIV-1 RNA
G3BP1 is a single-strand-speciﬁc endonuclease capable of binding
mRNA transcripts at the 3´UTR inside stress granules (Tourriere et al.,
2003, 2001) that control mRNA translation during cellular stress
Fig. 3. G3BP1 restricts HIV-1 but does not restrict other retroviruses. (A) 293T cells were transfected with 50 ng of shRNA targeting G3BP1 or shRNA control and
subsequently inoculated with single round-luciferase reporter retroviruses. Luciferase activity was measured 48 h after inoculation. The results presented are representative
of two independent experiments. (B–H) 293T cells were transfected with 50 ng of shRNA targeting G3BP1 or an shRNA control and 10 ng of luciferase reporter constructs
containing the different promoter regions: (B) HIV-1; (C) SIVmac; (D) MLV, (E) HBV-S1; (F) HBV Core; (G) CMV; (H) eF1α. Luciferase levels were measured 48 h after
transfection. The results presented here are from two independent experiments, performed in triplicate. Bars represent the average values of two separate experiments and
the error bars represent the standard error of the mean (SEM). Signiﬁcant differences are indicated by asterisks (Student’s T test; po0.05*, po0.01**, po0.001***).
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G3BP1 binds and sequesters HIV-1 transcripts inside cytosolic orga-
nelles, thus delaying translation and synthesis of viral proteins. To
investigate this, we performed RNA-immunoprecipitation (RIP) assays
in 293T cells transfected with a DNA plasmid encoding the full length
HIV-1 NL4-3BaL genome. Strikingly, our results show that G3BP1
interacted with all HIV-1 RNA transcripts (unspliced, single spliced or
multiple spliced) and upon silencing of G3BP1, a lesser amount of HIV-
1 transcripts was immunoprecipitated (Fig. 4A). As a positive control,
we were able to detect c-Myc mRNA (canonical G3BP1 mRNA target)
bound to G3BP1 in all samples. We were able to conﬁrm that there
was no unspeciﬁc precipitation of cellular RNA or G3BP1 by including
normal IgG antibodies as RIP negative control. Additionally, the
absence other mRNAs, like β-actin or Trim5α, allowed us to rule out
unspeciﬁc binding of G3BP1 to cellular RNAs. These data strongly
suggest that G3BP1 binds to HIV-1 transcripts.
To determine whether G3BP1 also binds to viral transcripts in
primary infected cells, we performed RIP experiments on HIV-1
infected macrophages cultured with or without IFNγþTNFα, and
measured the different HIV-1 RNA transcripts. Notably, viral RNA
transcripts were bound by G3BP1 at higher levels in IFNγþTNFα
stimulated macrophages, compared to unstimulated cells (Fig. 4B).
G3BP1 is a known component of stress granules (Tourriere et al.,
2003), and therefore we examined weather G3BP1 binds HIV-1 RNA
inside these organelles. We analyzed expression of G3BP1 and the
stress granule protein components G3BP2 (Matsuki et al., 2013),
TIA-R, TIA-1 (Kedersha et al., 1999), YBX-1 (Yang and Bloch, 2007)
and eIF3 (Kedersha et al., 2002) in IFNγþTNFα-stimulated macro-
phages by confocal ﬂuorescence microscopy, and compared them to
macrophages containing arsenic-induced stress granules (Fig. 4C).
Both G3BP1 and G3BP2 were localized in the cytoplasm of the
macrophages and partially co-localized; G3BP2 was found in peri-
nuclear, granular organelles that did not contain G3BP1. Expression
of TIA-R, TIA-1, YBX-1 and eIF3 was very low and diffuse on these
macrophages and did not co-localize with G3BP1 (images of sepa-
rate channels for each protein can be found in the Supplementary
material S1A–S1E). Notably, these stress granule proteins were
found to co-localize only in stress granules induced by sodium
arsenite treatment (indicated by the arrows, Fig. 4C). We alsoexamined unstimulated macrophages upon HIV-1 infection, or in
conjunction with IFNγþTNFα stimulation, but we did not observe
the formation of stress granules under these conditions either
(Supplementary material S1A–S1E). These results indicate that the
effect of G3BP1 on HIV-1 replication is independent of stress
granule formation or other stress granule proteins.
G3BP1 restricts HIV-1 replication in primary T-cells and macrophages
CD4þ T-cells are major targets for HIV-1 infection and can
become latently infected by the virus. Therefore, we analyzed
whether G3BP1 also restricts HIV-1 replication in primary T-cells.
G3BP1 was highly expressed in resting CD4þ naïve T-cells
(CD27þCD45RO-) and memory T-cells (CD27þCD45ROþ)
obtained from healthy blood donors (Fig. 5A) and no differences in
the expression levels were observed between both subpopula-
tions. In addition, G3BP1 was also highly expressed in resting T-
cells isolated from HIV-1 infected patients (participants of the
Amsterdam Cohort Studies), and no differences in expression were
observed between memory and naïve cells (Fig. 5B). Since pro-
ductive HIV-1 infection can only be established upon T-cell acti-
vation (Stevenson et al., 1990), we measured G3BP1 mRNA in IL-2-
stimulated T-cells and observed a signiﬁcant decrease in G3BP1
expression upon T-cell activation (Fig. 5C).
To further investigate whether G3BP1 controls HIV-1 replica-
tion in primary target cells, we silenced G3BP1 mRNA expression
in CD4þ T-cells and measured replication of the VSV-g pseudo-
typed GFP-reporter virus (Fig. 5D–F). Strikingly, silencing of G3BP1
resulted in higher HIV-1 replication (Fig. 5D). We conﬁrmed that
silencing resulted in lower G3BP1 mRNA levels (Fig. 5E), and
observed higher Pol mRNA upon silencing (Fig. 5F). We also
silenced G3BP1 expression in primary macrophages and measured
replication of HIV-1 VSV-g pseudotyped/Luciferase-reporter virus
(Fig. 5G–I). Similarly, silencing of G3BP1 in macrophages resulted
in higher HIV-1 replication, lower G3BP1 levels and higher Pol
mRNA levels (Fig. 5G–I). Furthermore, we observed that macro-
phages produced higher amounts of infectious viral particles when
G3BP1 was silenced (Fig. 5J).These results demonstrate that HIV-1
replication increases upon silencing of G3BP1 expression in
Fig. 4. G3BP1 binds to HIV-1 RNA transcripts independent of other stress granule proteins. (A) 293T cells were transfected with pNL4-3BaL and shRNA targeting G3BP1
or shRNA control, and samples were harvested for RIP 24 h post-transfection. Detection of the different HIV-1 RNA transcripts after cDNA synthesis was performed by qPCR
in triplicate. Values of the ratio of transcript levels cDNA obtained after RIP compared to levels in total RNA before RIP are given. (B) Monocytes were culture with or without
IFNγþTNFα for 5 days and infected with HIV-1 NL4-3BaL, and samples were harvested for RIP 72 h post-infection. Detection of the different HIV-1 RNA transcripts after cDNA
synthesis was performed by PCR and agarose-gel electrophoresis, and the intensity of the PCR product band was quantiﬁed. Transcripts levels cDNA obtained after RIP were
compared to levels in total RNA before RIP. Values presented here correspond to log2 transformed ratio of the intensity of the PCR products. (C) Monocytes were culture with
IFNγþTNFα for 5 days, or treated with Sodium Arsetine (ARS). Cellular localization of G3BP1 (in red) and stress granule proteins G3BP2, TIA-R, TIA-1, YBX-1 and eIF3 (in
green) was analyzed by laser scanning confocal microscopy, 24 h post-infection. Nuclei were stained with Hoechst (in blue). Merged images of all channels are shown.
Images of separate channels can be found in Supplementary material S1A–S1E. White arrows point to stress granule organelles where the two stress granule proteins co-
localize.
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restricts viral replication in these cells.Discussion
In this study, we have discovered that human G3BP1 inhibits
HIV-1 replication after integration of the DNA provirus. We have
shown that G3BP1 is induced by IFNγþTNFα in macrophages and
that it is highly expressed in resting T-cells. Silencing of G3BP1 in
macrophages and primary T-cells increased viral replication and
HIV-1-mediated gene expression, as well as viral mRNA and pro-
tein levels, and production of infectious particles. Our results
demonstrate that G3BP1 binds HIV-1 full length and spliced RNA
transcripts in the cytosol of infected macrophages, suggesting that
G3BP1 captures viral transcripts preventing translation or for
packaging into viral particles.
In our previous studies, we have shown that IFNγþTNFα sti-
mulation of macrophages results in inhibition of viral replication at
late stages of the HIV-1 replication cycle (Cobos Jiménez et al., 2012).
Therefore we used these cells to identify novel cellular factors thatact at late stages of the viral replication cycle. Transcriptome analysis
allowed us to select genes that are differentially expressed among
activated macrophages. Among the genes that were exclusively
regulated in IFNγþTNFα stimulated macrophages, but not during
differentiation of monocytes into macrophages or upon activation
with other cytokines (IL-4, IL-10 and M-CSF), 19 genes have pre-
viously been indicated to possess antiviral characteristics or were
involved in viral infections (Table 1). One of these genes, MX1, has
recently been reported to be an IFN-α induced gene, capable of
inhibiting inﬂuenza virus but not HIV-1 replication (Goujon et al.,
2013). Accordingly, we identiﬁed G3BP1, which acts at a post-
integration step and captures viral RNA transcripts, therefore pre-
venting viral protein synthesis and virus particle production.
Our results strongly suggest that G3BP1 speciﬁcally inhibited
for HIV-1 replication, since silencing of G3BP1 did not affect
replication of other retroviruses such as SIVmac or MLV. Similarly,
while G3BP1 affects HIV-1 LTR-driven gene expression, it did not
alter other viral or cellular promoter activity, including SIVmac and
MLV promoters. This suggests that speciﬁc motifs in the HIV-1
promoter region that are absent in the other viral promoters, allow
G3BP1 to bind and capture HIV-1 transcripts in the cytosol. Our
Fig. 5. Role of G3BP1 in primary T-cells and macrophages. (A) Expression of G3BP1 relative to β-actin, in memory and naïve T-cells derived from healthy blood donors or
(B) HIV-1 seropositive patients, was measured by qPCR in triplicate and levels were normalized to a housekeepign gene. Each dot represents result from independent donors.
(C) Expression of G3BP1 relative to a housekeeping gene, in PBMC and PBMC stimulated with IL-2. (D–F) PBMC isolated form 2 donors were inoculated with the VSV-G/YU2-
GFP virus and 24 h later transduced with lentivirus expressing shRNA control or shRNA against G3BP1; (D) GFP positive cells were measured 4 days later; (E) to conﬁrm
G3BP1 downregulation, G3BP1 mRNA levels relative to a housekeeping gene were measured in cells from one donor; (F) to show the effect of G3BP1 downregulation on HIV-
1 replication in CD4þ T-cells, HIV-1 Pol mRNA levels relative to a housekeeping gene were measured in cells from one donor. These results are representative from
3 independent experiments. (G–I) Monocytes from 3 donors were cultured for 4 days and subsequently transfected with siRNA libraries targeting G3BP1 or non-targeting
siRNAs as control, and inoculated with the VSV-G/NL4-3Luc virus at day 7; (G) luciferase levels were measured 72 h after inoculation. (H) To conﬁrm G3BP1 downregulation,
G3BP1 mRNA levels relative to a housekeeping gene were measured; (I) to show the effect of G3BP1 downregulation on HIV-1 replication in macrophages, HIV-1 Pol mRNA
levels relative to a housekeeping gene were measured. These results are representative from 3 independent experiments. (J) Monocytes from 4 donors were cultured for
5 days and subsequently transduced with lentiviruses expressing shRNA control or shRNA against G3BP1. Cells were infected 48 h later with VSV-G-NL4-3BaL. Supernatant
samples were collected after 24 days and assessed for infectious virus production in TZM-bl reporter cells. Signiﬁcant differences are indicated by asterisks (A-C, H, I, J:
Student’s T-test, G: Mixed linear model, repeated covariance: Diagonal, D: Ratio paired T-Test; po0.05*, po0.01**, po0.001***).
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through its interaction with viral transcripts, rather than inhibiting
their transcription or translation; yet the complete mechanism of
action of G3BP1 still needs to be elucidated in detail.
G3BP1 is required for stress granule formation and controls
mRNA translation (Tourriere et al., 2003). We demonstrate that
G3BP1 is able to bind HIV-1 RNA transcripts independently of stress
granule formation or other stress granules proteins. Formation of
stress granules and their components are known to interact with
viruses, resulting in either enabling or inhibiting viral replication
(Reineke and Lloyd, 2013). It has been described that PKR (or
eukaryotic translation initiation factor 2 alpha-kinase) is also
required for stress granule formation upon activation by ds-RNA.
The interaction between PKR, G3BP1 and RIG-I-like receptors inside
stress granules is required for IFN-β production during infection
with Inﬂuenza A virus lacking the NS1 viral protein (Onomoto et al.,
2012). Interaction of all these components may facilitate recognition
of viral RNA in the cytoplasm by RIG-I-like sensors (Onomoto et al.,2012), indicating a strong relationship between G3BP1, stress
granules and innate immune responses. However, our data strongly
suggest that G3BP1-mediated restriction of HIV-1 is not mediated
via stress granules, since G3BP1 did not co-localize with these
organelles in macrophages. In fact, a recent study (Valiente-
Echeverria et al., 2014) has shown that HIV-1 is able to inhibit
canonical stress granule formation, and that the interaction of
G3BP1 and HIV-1 Gag mediates disassembly of stress granules. In
this report, the authors indirectly show that G3BP1 is found toge-
ther with viral RNA in PBMCs isolated from HIV-1 infected patient
that progresses to AIDS (Valiente-Echeverria et al., 2014) but not
associated with stress granules. This study lends credence to our
ﬁndings that G3BP1 can interact with HIV-1 RNA outside stress
granules, and also indicated that G3BP1 can also interact with other
viral proteins.
Moreover, G3BP1 can also mediate innate immune responses
independently of its function related to stress granules. G3BP1,
together with G3BP2 and CAPRIN1 (also an RNA binding protein,
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Genes (ISGs), and thus induce IFN-β production and an antiviral
response against Dengue Virus (DENV), independently of stress
granule formation (Bidet et al., 2014). Dengue Virus is able to
bypass this mechanism by producing decoy viral RNAs (sfRNA)
that bind to these RBPs, and thereby prevent mediation of the
interferon response (Bidet et al., 2014). Our data strongly suggest
that G3BP1 inhibits HIV-1 replication by binding HIV-1 RNA
transcripts, suggesting it could also be involved in hampering the
interferon response in primary HIV-1 target cells and thereby
assisting HIV-1 in escaping induction of these immune responses.
HIV-1 reservoirs in primary target cells are a major hurdle in
HIV-1 eradication, since they allow continuous viral replication. Our
ﬁndings indicate that while HIV-1 can replicate in primary cells,
replication is restricted in cells that express high levels of G3BP1
such as resting T-cells and IFNγþTNFα-activated macrophages.
Thus, it is possible that G3BP1 limits translation of HIV-1 mRNA in
resting cells, but upon T-cell activation, lower G3BP1 expression
may then allow efﬁcient translation of viral transcripts, resulting in
productive viral replication. Subsequent studies should deﬁnitely
focus on deciphering the mechanism by which G3BP1 restricts HIV-
1 and other viruses. Further research on the role of G3BP1 in pri-
mary immune cells will not only give us insight regarding HIV-1
infection and viral reservoirs but also about other infectious agents,
like Inﬂuenza or Dengue virus, that also interact with G3BP1 during
their replication cycle. This knowledge will also provide new
opportunities to ﬁnd novel targets and design new therapeutic
strategies towards the elimination of the viral reservoir as part of a
sterilizing cure for HIV-1 infection (Deeks et al., 2012).Materials and methods
Isolation of monocytes and cell culture
Monocytes and peripheral blood lymphocytes (PBL) were
obtained from buffy coats from healthy blood donors. Written
informed consents were obtained from all donors in accordance
with the ethical principles set out in the declaration of Helsinki.
This study was approved by the Medical Ethics Committee of the
Academic Medical Center and the Ethics Advisory Body of the
Sanquin Blood Supply Foundation in Amsterdam, The Netherlands.
Peripheral blood mononuclear cells (PBMC) were isolated from
buffy coats using Lymphoprep (Axis-Shield) density gradient
centrifugation. Monocytes were isolated by adherence to plastic
and cultured in Iscove’s modiﬁed Dulbecco’s medium (IMDM)
supplemented with 10% [v/v] heat-inactivated human pooled
serum (HPS), penicillin (100 U/ml; Invitrogen), streptomycin
(100 mg/ml) and ciproxin (5 μg/ml; Bayer) for 5 days in the pre-
sence of different cytokines: M-CSF (50 ng/ml; Sigma-Aldrich),
IFN-γ (50 U/ml; Sigma-Aldrich) in combination with TNF-α
(12.5 ng/ml; Peprotech), IL-4 (50 ng/ml; Peprotech), IL-10 (50 ng/
ml; Peprotech), or medium alone at 37 °C in a humidiﬁed atmo-
sphere supplemented with 5% CO2
PBMC were also obtained from HIV-1 seropositive participants
of the Amsterdam Cohort Studies. All individuals were infected
with HIV-1 subtype B. The Amsterdam Cohort Studies are con-
ducted in accordance with the ethical principles set put in the
declaration of Helsinki and written consent was obtained prior to
data collection. PBMC from healthy blood donors and HIV-1
positive individuals were sorted into CD4þ naïve T-cells
(CD27þCD45RO-) and memory T-cells (CD27þCD45ROþ) by ﬂow
cytometry with the FACS Canto II (BD Biosciences). Additionally,
PBMC isolated from healthy blood donors were cultured for 3 days
with IMDM supplemented with 10% [v/v] heat-inactivated fetalbovine serum, penicillin, streptomycin, ciproxin and IL-2 (20 U/ml;
Chirion Benelux).
HEK293T cells were cultured in Dulbecco's Modiﬁed Eagle
Medium (DMEM) without Hepes (Lonza), supplemented with 10%
[v/v] inactivated fetal calf serum, penicillin (100 U/ml) and strep-
tomycin (100 μg/ml), at 37 °C in a humidiﬁed atmosphere sup-
plemented with 10% CO2.
Transcriptional proﬁles study and data mining
At day 5 the medium was removed and Monocyte Derived
Macrophages (MDM) were harvested with TriPure Isolation
reagent (Roche). RNA was isolated according to the manufacturer’s
protocol. RNA samples were cleaned with RNeasy Mini Spin col-
umns (Qiagen RNeasy Mini Kit, Qiagen) according to the clean-up
protocol from the manufacturer. The concentration was analyzed
with the Nanodrop ND-1000 spectrophotometer and A260/280
values were above 2.0 for all samples. Microarrays were performed
in the Illumina HumanHT-12 v4.1 Expression BeadChip kit.
Background-subtracted data were normalized by Quantiles in R/
Bioconductor. All datasets have been deposited in Geoproﬁles:
SubSeries GSE49240 (samples GSM1195728-39), part of the
SuperSeries GSE35495 (Martinez et al., 2013). Genes with fold
changeZ2 were considered differentially expressed. Statistical
differences and data processing was performed in TMev v4.8.1
(Saeed et al., 2003).
qPCR
For mRNA quantiﬁcation, cDNA from TriPure-isolated RNA was
prepared using the M-MLV Reverse Transcriptase kit (Promega)
using an oligo-dT primer, and the qPCR was performed in a
Lightcycler 480II (Roche) with SYBR Green I Master or Roche
Probes and Master mix (Roche). Primer sequences are available
upon request. The following cycling conditions were used: dena-
turation for 95 °C for 10 min; ampliﬁcation: 40 cycles of 95 °C for
10 s, 58 °C for 20 s and 72 °C for 30 s (Sybr green); or denaturation:
95 °C for 10 s, ampliﬁcation: 55 cycles of 95 °C for 15 s, 60 °C for
60 s (Dual hydrolysis probe).
Speciﬁcity of the primer pairs was conﬁrmed by melting curve
analysis of the PCR products and relative copy numbers were
calculated using the LightCycler 480 software, version 1.5. Differ-
ences in expression levels were analyzed using GraphPad Prism v5
(GraphPad software).
Viruses and expression vectors
HIV-1 NL4-3 Ba-L, single-round luciferase viruses pseudotyped
with the vesicular stomatitis glycoprotein (VSV-G) (NL4-3Luc,
SIVmacLuc, MLVLuc) and single round YU2-GFP virus pseudotyped
with VSV-G were produced by transient transfection of HEK293T
cells with pNL4-3BaL, or pCMV-VSV-G in combination with pNL4-
3.Luc.R-E-, pSIVmac.Luc.R-E- (Mariani et al., 2003), pMLV-MP71Luc
(Schambach et al., 2000) and helper construct pHIT60 (Soneoka
et al., 1995), or pYU2, using a calcium phosphate method (He et al.,
1995). Infectious virus was harvested at 48 and 72 h after trans-
fection and ﬁltered through a 0.22 μm ﬁlter. NL4-3 Ba-L titers were
determined on PHA-stimulated PBMC as described previously
(van't Wout et al., 2008). Titers of the VSV-G pseudotyped single-
round luciferase and GFP viruses were determined on
HEK293T cells.
pLKO.1-puro constructs expressing a shRNA against G3BP1 or
shRNA control from the MISSION™ TRC-Hs 1.0 library (Root et al.,
2006) were tested (1: G3BP1 TRCN0000008719, 2: G3BP1
TRCN0000008720, 3: G3BP1 TRCN0000008721, 4: G3BP1
TRCN0000008722, 5. G3BP1 TRCN0000008723 and empty vector
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testes, shRNA3 was the most effective in silencing G3BP1 expres-
sion, and was therefore used for subsequent experiments. Lenti-
viral vectors were produced by co-transfection of pLKO.1 con-
structs expressing shRNA-3 or the SHC001 control, and pCMV-
VSV-G, pMDLgp and pRSV-Rev in HEK293T cells (Dull et al., 1998).
Lentiviral vector supernatant was concentrated by centrifugation
at 50,000g for 2 h directly after harvesting. Lentiviral vector titers
were determined in HEK293T cells. Equal amounts of lentiviral
vector as determined by p24 ELISA were used to inoculate
target cells.
The LTR-Luciferase reporter construct pBlue30 LTR-luc was a
kind gift from Dr. R. Jeeninga and Dr. B. Berkhout, Academic
Medical Center, Amsterdam, The Netherlands (Jeeninga et al.,
2000). The pGL 4.51 Luc2/CMV/Neo vector (Promega) was used for
evaluating luciferase expression mediated by the CMV promoter
region. To generate the hEF1α-Luc construct, expressing luciferase
under control of the human elongation factor 1 promoter, the
luciferase gene was ampliﬁed using primers containing restriction
sites for BamHI and KpnI. The ampliﬁcation product was digested
with these enzymes and ligated after the hEF1α promoter in a
lentiviral vector digested with the same enzymes (Zufferey et al.,
1998). The luciferase reporters under control of the different HBV
promoters were generated as described by Du et al. (2008), with
minor modiﬁcations to the primers to make them suitable to the
HBV adw subtype. The different promoter sequences were ampli-
ﬁed by PCR from the R9 vector, which contains a 1.2x overlength
HBV DNA genome (subtype adw) in a pGEM 7zfþ backbone
(kindly provided by Dr. Baumert) (Baumert et al., 1996). All con-
structs were validated by BDT sequencing.
G3BP1 silencing
Monocytes were seeded at density of 50.000 cells per well (in
96-well plates) and transfected at day 4 with 50ng of siGENOME
siRNA pool libraries targeting Human G3BP1 (ThermoFisher Sci-
entiﬁc) using DarmaFECT 4 Transfection reagent (ThermoFisher
Scientiﬁc) in antibiotic-free medium containing 5% HPS, according
to manufacturer´s protocol. After 48 h, the transfection medium
was replaced by culture medium containing antibiotics and 10%
HPS, and 24 h later cells were inoculated with 15.000 TCID50 units
of VSV-g/NL4-3Luc. Luciferase activity was analyzed 72 h after
inoculation as described above. Differences in luciferase levels
were analyzed with a mixed linear model in SPSS 10 (IBM).
PBMCs were isolated form buffy coats and stimulated with IL-2
for 24 h. Next, CD4þ cells were selected with the CD4þ T-Cell
Isolation Kit (Miltengy Biotec) and inoculated with the DNase
treated VSV-G-YU2 virus at a MOI of 1. After 48 h, cells were
transduced with lentiviruses expressing the shRNA control or
shRNA-3 targeting G3BP1, at a MOI of 40. RNA samples were taken
48 h after transduction. GFP positive cells were measured 4 days
after transduction by ﬂow cytometry with the FacsCanto II (BD
Biosciences) and the results were analyzed in FlowJo, version 9.4.3
(Tree Star).
Monocytes were cells were transduced with lentiviruses
expressing the shRNA control or shRNA-3 targeting G3BP1, at a
MOI of 40. Cells were infected with VSV-G-NL4-3BaL 48 h later, at
an MOI of 0.002. Supernatant samples were collected 24 days later,
and virus production was assessed on TZM-bl reporter cells.
Western blot analysis
Cells were harvested with trypsin-EDTA (PAA, Pasching Aus-
tria), collected and washed with PBS and centrifuged at 400g for
10 min. The cell pellet was lysed in 200 μl of RIPA lysis buffer
(150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%SDS, 50 mM Tris, pH 8.0) supplemented with Completes EDTA
free protease inhibitor (Roche). The lysate was denatured at 70 °C
for 10 min in 1NuPAGE LDS sample buffer (Invitrogen) and 0.1 M
DTT. Proteins were separated by electrophoresis on a 10% Bis-Tris
gel (NuPAGE 10% Bis–Tris precast gel) together with the Odyssey
Protein Weight Marker (LI-COR, Lincoln, NE, USA) using MES SDS
running buffer (Invitrogen). Subsequently, proteins were trans-
ferred to a nitrocellulose membrane (Protran, Schleicher & Schuell,
Dassel, Germany; 2 h 150 V) using NuPAGE transfer buffer. Blots
were stained over night at 4 °C in PBS (Gibco) supplemented with
0.01% Tween 20 (Merck) and 1% Protifar (Nutricia, Schiphol, The
Netherlands) with a polyclonal goat anti-β-actin antibody (1:200;
Santa Cruz) or an in-house polyclonal rabbit anti-p24 antibody
(1:100). IRDye 680 conjugated donkey anti-rabbit IgG and IRDye
680 donkey anti-goat IgG (1:15.000; LI-COR, Lincoln, NE, USA)
were used as secondary antibodies to visualize the proteins using
the Odyssey infrared image system (LI-COR).
RNA-immuno precipitation assays (RIP)
293T cells were transfected with NL4-3BaL expression con-
struct together with pLKO.1 construct expressing shRNA-3 tar-
geting G3BP1 and samples were harvested 48 h after transfection.
Monocytes were stimulated or not with IFNγþTNFα for 5 days
and then inoculated with HIV-1 NL4-3 Ba-L. Samples were isolated
72 h after inoculation. RNA Immunoprecipitation was performed
with the EZ-Magna RIP™-RNA Binding Immunoprecipitation Kit
(Millipore) together with the RIPAbþ™ G3BP1 – RIP Antibody and
Primer set (Millipore), according to the manufacturer´s protocol.
Reactions using normal mouse-IgG antibodies were used as
negative controls. cDNA was synthesized form the RNA isolated
after RIP, using Random Primers and the M-MLV reverse tran-
scriptase (Promega). PCR was performed to detect HIV-1 cDNA and
PCR products were visualized after 2% agarose gel electrophoresis
containing Ethidium Bromide (Promega), with a UV-light tran-
silluminator. The PCR product band intensity was quantiﬁed using
the Image Studio Lite software v3.1 (LI-COR). Additionally, qPCR
was also performed to detect HIV-1 cDNA using SYBRgreen Mas-
terMix (Roche) as described above. We performed a qPCR using c-
Myc primers, as a positive control for the G3BP1 canonical target,
and using primers for β-actin and Trim5α as negative controls for
unspeciﬁc precipitation of cellular mRNAs.
Immunoﬂuorescence analysis
Monocytes were seeded on glass coverslips and cultured with
or without IFNγþTNFα for 5 days. Subsequently cells were
inoculated with HIV-1 NL4-3 BaL for 24 h or treated with Sodium
Arsenite (0.5 mM; Sigma-Aldrich) for 30 min. Cells were ﬁxed with
1% paraformaldehyde in PBS for 30 min, and washed with PBS
three times. After quenching with 10 mM glycine in PBS, cells were
incubated for 20 min with methanol at 20 °C. Cells were then
permeabilized with 0.1% Triton in PBS for 10 min. Coverslips were
incubated with primary antibodies diluted in PBS with 5% FCS for
1 h (Mouse-anti-G3BP1, BD Transduction, rabbit-anti-G3BP2
(Assay Biotech), rabbit-anti-eIF3α, rabbit-anti-TIA-1/R (Santa
Cruz), rabbit-anti-YBX1 (Bioke)). Detection of primary antibodies
was done with donkey-α-mouse-Cy3 or goat-α-rabbit-Alexa488
(1:500; Jackson). Nuclei were stained with Hoechst 33342. The
coverslips were mounted with Prolong Gold (Invitrogen) and
analyzed using a Laser Scanning Confocal Microscope SP8-X (Leica
Microsystems). Images were taken at 10241024 pixel resolution
using the same settings and processed with the LAS-AFlite v2.6.0
software (Leica Microsystems).
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